Results 71 to 80 of about 357,544 (339)
Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Molecular Oncology, EarlyView.Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon +4 more
wiley +1 more source
Frontiers in Pharmacology, 2018 Objective: The aim of this study was to explore the tolerance, variability, and pharmacokinetics (PK) of albumin-bound paclitaxel (QL, HR, ZDTQ) among Chinese breast cancer patients.Methods: Three randomized, open-label, two-period crossover ...
Qingmei Li +8 more
doaj +1 more source
The Role of TLR4 in the Paclitaxel Effects on Neuronal Growth In Vitro [PDF]
, 2013 Paclitaxel (Pac) is an antitumor agent that is widely used for treatment of solid cancers. While being effective as a chemotherapeutic agent, Pac in high doses is neurotoxic, specifically targeting sensory innervations.
Gutkin, DW +3 more
core +2 more sources
Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma
Molecular Oncology, EarlyView.Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra +6 more
wiley +1 more source
A comparison of paclitaxel and vinblastine induced giant cell formation in murine NK/Ly lymphoma
Біологічні студії, 2011 We compared giant cell formation in murine NK/Ly lymphoma under treatment with anticancer drugs – vinblastine or paclitaxel. It was found that vinblastine caused an appearance of bigger cells than paclitaxel did, whereas paclitaxel induced more rapid ...
R. O. Horbay +2 more
doaj +1 more source
Frontiers in Oncology, 2021 Angiographically silent cystoid macular edema (CME) is a rare complication from nab-paclitaxel. Here we report a 45-year-old woman with breast cancer who developed CME after several months of treatment with albumin-bound paclitaxel (nab-paclitaxel).
Suna Ye +8 more
doaj +1 more source
RAB family gene expression in breast cancer cells under influence of paclitaxel [PDF]
, 2011 The aim of this study was to investigate the role of paclitaxel on RAB family of genes in primary breast cancer cell lines. The cancer breast cells obtained from 40 women during mastectomy were used to address this issue. The group included patients with
Andrzej Wilkolaski +3 more
core +1 more source
Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. [PDF]
, 2017 Breast cancer remains the leading cause of cancer death in women owing to metastasis and the development of resistance to established therapies. Macrophages are the most abundant immune cells in the breast tumor microenvironment and can both inhibit and ...
A Fantozzi +66 more
core +2 more sources
Bio-Inspired Amphiphilic Block-Copolymers Based on Synthetic Glycopolymer and Poly(Amino Acid) as Potential Drug Delivery Systems [PDF]
, 2020 In this work, a method to prepare hybrid amphiphilic block copolymers consisting of biocompatible synthetic glycopolymer with non-degradable backbone and biodegradable poly(amino acid) (PAA) was developed.
Dobrodumov, Anatoliy +10 more
core +1 more source
Journal of Clinical Oncology, 2019 PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated
P. Schmid +28 more
semanticscholar +1 more source